JP2020536109A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020536109A5 JP2020536109A5 JP2020519404A JP2020519404A JP2020536109A5 JP 2020536109 A5 JP2020536109 A5 JP 2020536109A5 JP 2020519404 A JP2020519404 A JP 2020519404A JP 2020519404 A JP2020519404 A JP 2020519404A JP 2020536109 A5 JP2020536109 A5 JP 2020536109A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- amino acid
- use according
- seq
- human
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 11
- 230000000694 effects Effects 0.000 claims 11
- 101000678236 Homo sapiens 5'-nucleotidase Proteins 0.000 claims 8
- 206010028980 Neoplasm Diseases 0.000 claims 7
- 101100501552 Homo sapiens ENTPD1 gene Proteins 0.000 claims 6
- 102100022464 5'-nucleotidase Human genes 0.000 claims 4
- 108091006112 ATPases Proteins 0.000 claims 4
- 102000057290 Adenosine Triphosphatases Human genes 0.000 claims 4
- 108010080422 CD39 antigen Proteins 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 102000045309 human NT5E Human genes 0.000 claims 4
- 102000004169 proteins and genes Human genes 0.000 claims 4
- 108090000623 proteins and genes Proteins 0.000 claims 4
- 230000002401 inhibitory effect Effects 0.000 claims 3
- 102000009490 IgG Receptors Human genes 0.000 claims 2
- 108010073807 IgG Receptors Proteins 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 108010047482 ectoATPase Proteins 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 102000035195 Peptidases Human genes 0.000 claims 1
- 108091005804 Peptidases Proteins 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 230000003472 neutralizing effect Effects 0.000 claims 1
- 125000002796 nucleotidyl group Chemical group 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 235000019833 protease Nutrition 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762568812P | 2017-10-06 | 2017-10-06 | |
| US62/568,812 | 2017-10-06 | ||
| US201862686143P | 2018-06-18 | 2018-06-18 | |
| US62/686,143 | 2018-06-18 | ||
| PCT/EP2018/077217 WO2019068907A1 (en) | 2017-10-06 | 2018-10-05 | RESTORATION OF T CELL ACTIVITY BY AXIS CD39 / CD73 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020536109A JP2020536109A (ja) | 2020-12-10 |
| JP2020536109A5 true JP2020536109A5 (cg-RX-API-DMAC10.html) | 2021-10-21 |
| JP7274469B2 JP7274469B2 (ja) | 2023-05-16 |
Family
ID=63799006
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020519404A Active JP7274469B2 (ja) | 2017-10-06 | 2018-10-05 | Ｃｄ３９／ｃｄ７３軸によるｔ細胞活性の回復 |
Country Status (11)
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3153526T3 (da) | 2008-01-31 | 2020-12-14 | Inst Nat Sante Rech Med | Antistoffer mod human cd39 og anvendelse deraf til inhibering af aktivitet af t-regulatoriske celler |
| GB2545676A (en) * | 2015-12-21 | 2017-06-28 | Dublin Inst Of Tech | Prediction of therapeutic response using vibrational spectroscopy |
| EP3596124A1 (en) | 2017-03-16 | 2020-01-22 | Innate Pharma | Compositions and methods for treating cancer |
| CA3071540A1 (en) | 2017-07-31 | 2019-02-07 | Tizona Therapeutics | Anti-cd39 antibodies, compositions comprising anti-cd39 antibodies and methods of using anti-cd39 antibodies |
| AU2019263850A1 (en) | 2018-05-03 | 2020-11-19 | Shanghai Epimab Biotherapeutics Co., Ltd. | High affinity antibodies to PD-1 and LAG-3 and bispecific binding proteins made therefrom |
| CA3099893A1 (en) | 2018-06-18 | 2019-12-26 | Innate Pharma | Compositions and methods for treating cancer |
| SG11202111106WA (en) | 2019-04-23 | 2021-11-29 | Innate Pharma | Cd73 blocking antibodies |
| JP7471016B2 (ja) * | 2019-08-21 | 2024-04-19 | ハーバー・バイオメド・（シャンハイ）・カンパニー・リミテッド | 抗ｃｄ７３抗体およびその適用 |
| CN112714768B (zh) * | 2019-08-27 | 2025-02-18 | 科望(苏州)生物医药科技有限公司 | 新型抗cd39抗体 |
| CN110407941B (zh) * | 2019-09-25 | 2020-01-14 | 上海岸迈生物科技有限公司 | Cd39的高亲和力抗体及其用途 |
| US12391756B2 (en) | 2019-11-05 | 2025-08-19 | Jacobio Pharmaceuticals Co., Ltd. | Binding molecule specific for CD39 and use thereof |
| CN115135386A (zh) * | 2019-12-19 | 2022-09-30 | 得克萨斯州大学系统董事会 | 用于治疗胶质母细胞瘤的方法 |
| CN114106160A (zh) * | 2020-08-28 | 2022-03-01 | 安源医药科技（上海）有限公司 | 抗SARS-CoV-2病毒单克隆抗体及应用 |
| US20220133902A1 (en) * | 2020-11-04 | 2022-05-05 | Heidelberg Pharma Research Gmbh | Composition Comprising a Combination of Immune Checkpoint Inhibitor and Antibody-Amatoxin Conjugate for Use in Cancer Therapy |
| TW202302638A (zh) * | 2021-02-19 | 2023-01-16 | 美商健生生物科技公司 | 用於靶向調節性ｔ細胞以增強免疫監視之材料及方法 |
| WO2022194988A2 (en) | 2021-03-19 | 2022-09-22 | Heidelberg Pharma Research Gmbh | B-lymphocyte specific amatoxin antibody conjugates |
| AR128688A1 (es) | 2022-03-03 | 2024-06-05 | Arcus Biosciences Inc | Anticuerpos anti-cd39 y uso de los mismos |
| CN119403837A (zh) * | 2022-06-08 | 2025-02-07 | 上海华奥泰生物药业股份有限公司 | Cd39/cd73双特异性抗原结合蛋白及其用途 |
| CN121240867A (zh) * | 2023-03-21 | 2025-12-30 | 比姆医疗股份有限公司 | 免疫抑制剂抗性修饰的同种异体修饰的免疫细胞及其使用方法 |
| CN120992939B (zh) * | 2025-10-27 | 2025-12-26 | 苏州旭光科星抗体生物科技有限公司 | 一种可溶性cd39蛋白含量检测试剂盒及其应用 |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5567610A (en) | 1986-09-04 | 1996-10-22 | Bioinvent International Ab | Method of producing human monoclonal antibodies and kit therefor |
| US5229275A (en) | 1990-04-26 | 1993-07-20 | Akzo N.V. | In-vitro method for producing antigen-specific human monoclonal antibodies |
| US5660827A (en) | 1992-03-05 | 1997-08-26 | Board Of Regents, The University Of Texas System | Antibodies that bind to endoglin |
| US6387645B1 (en) * | 1998-07-16 | 2002-05-14 | Hyseq, Inc. | Methods and materials relating to novel CD39-like polypeptides |
| EP2439273B1 (en) | 2005-05-09 | 2019-02-27 | Ono Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics |
| HRP20151102T1 (xx) | 2005-07-01 | 2015-11-20 | E. R. Squibb & Sons, L.L.C. | Humana monoklonska antitijela za ligand programirane smrti 1 (pd-l1) |
| WO2009014708A2 (en) | 2007-07-23 | 2009-01-29 | Cell Genesys, Inc. | Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof |
| DK3153526T3 (da) | 2008-01-31 | 2020-12-14 | Inst Nat Sante Rech Med | Antistoffer mod human cd39 og anvendelse deraf til inhibering af aktivitet af t-regulatoriske celler |
| ES2639857T3 (es) | 2008-02-11 | 2017-10-30 | Cure Tech Ltd. | Anticuerpos monoclonales para el tratamiento del tumor |
| US8168757B2 (en) | 2008-03-12 | 2012-05-01 | Merck Sharp & Dohme Corp. | PD-1 binding proteins |
| SMT202500126T1 (it) | 2008-12-09 | 2025-05-12 | Hoffmann La Roche | Anticorpi anti-pd-l1 e loro uso per potenziare la funzione dei linfociti t |
| HRP20171653T1 (hr) | 2009-11-24 | 2017-12-15 | Medimmune Limited | Vezna sredstva koja služe ciljano protiv b7-h1 |
| ES2669310T3 (es) | 2011-04-20 | 2018-05-24 | Medimmune, Llc | Anticuerpos y otras moléculas que se unen con B7-H1 y PD-1 |
| BR112014002353B1 (pt) | 2011-08-01 | 2022-09-27 | Genentech, Inc | Usos de antagonistas de ligação do eixo pd-1 e inibidores de mek, composições farmacêuticas, e kit |
| SG11201404177PA (en) * | 2012-02-07 | 2014-08-28 | Innate Pharma | Mica binding agents |
| FR3011240A1 (fr) | 2013-10-01 | 2015-04-03 | Centre Nat Rech Scient | Inhibiteurs de 5'-nucleotidases et leurs utilisations therapeutiques |
| DK3081576T3 (da) | 2013-12-12 | 2019-10-21 | Shanghai hengrui pharmaceutical co ltd | Pd-1-antistof, antigenbindende fragment deraf og medicinsk anvendelse deraf |
| JP6657182B2 (ja) | 2014-04-25 | 2020-03-04 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 癌治療用のｃｄ７３阻害剤としてのプリン誘導体 |
| WO2016131950A1 (en) | 2015-02-20 | 2016-08-25 | Innate Pharma | Cd73 blockade |
| CA2957813C (en) * | 2014-10-10 | 2025-07-08 | Innate Pharma | CD73 BLOCKAGE |
| EP3218406B2 (en) | 2014-11-10 | 2024-10-02 | Medimmune Limited | Binding molecules specific for cd73 and uses thereof |
| WO2016075176A1 (en) * | 2014-11-11 | 2016-05-19 | Medimmune Limited | Therapeutic combinations comprising anti-cd73 antibodies and a2a receptor inhibitor and uses thereof |
| WO2016081748A2 (en) | 2014-11-21 | 2016-05-26 | Bristol-Myers Squibb Company | Antibodies against cd73 and uses thereof |
| EP3362475B1 (en) * | 2015-10-12 | 2023-08-30 | Innate Pharma | Cd73 blocking agents |
| AU2016359790A1 (en) * | 2015-11-23 | 2018-06-21 | Innate Pharma | CD39 vascular isoform targeting agents |
| WO2017098421A1 (en) | 2015-12-08 | 2017-06-15 | Glaxosmithkline Intellectual Property Development Limited | Benzothiadiazine compounds |
| AU2016366548C1 (en) | 2015-12-09 | 2024-07-25 | Bioatla, Llc | Humanized anti-CD73 antibodies |
| HUE063388T2 (hu) | 2016-01-08 | 2024-01-28 | Arcus Biosciences Inc | Ekto-5'-nukleotidáz modulátorok és ezek alkalmazása |
| WO2017153952A1 (en) | 2016-03-10 | 2017-09-14 | Glaxosmithkline Intellectual Property Development Limited | 5-sulfamoyl-2-hydroxybenzamide derivatives |
| EP3541396A4 (en) | 2016-11-18 | 2020-07-22 | Arcus Biosciences, Inc. | CD73-MEDIATED IMMUNOSUPPRESSION INHIBITORS |
| EP3596124A1 (en) * | 2017-03-16 | 2020-01-22 | Innate Pharma | Compositions and methods for treating cancer |
| BR112020009655A8 (pt) * | 2017-11-15 | 2023-03-21 | Innate Pharma | Anticorpo, usos de um anticorpo e uso de uma combinação farmacêutica |
| SG11202111106WA (en) * | 2019-04-23 | 2021-11-29 | Innate Pharma | Cd73 blocking antibodies |
| CN119409834A (zh) * | 2019-08-12 | 2025-02-11 | 北京恩瑞尼生物科技股份有限公司 | 用于通过cd39表达细胞的adcc靶向促进和增强t细胞介导的免疫反应的方法和组合物 |
-
2018
- 2018-10-05 SG SG11202002192QA patent/SG11202002192QA/en unknown
- 2018-10-05 CN CN201880064186.3A patent/CN111542539B/zh active Active
- 2018-10-05 WO PCT/EP2018/077217 patent/WO2019068907A1/en not_active Ceased
- 2018-10-05 BR BR112020006809-8A patent/BR112020006809A2/pt unknown
- 2018-10-05 EP EP18783458.5A patent/EP3692068B1/en active Active
- 2018-10-05 AU AU2018346447A patent/AU2018346447B2/en active Active
- 2018-10-05 JP JP2020519404A patent/JP7274469B2/ja active Active
- 2018-10-05 CA CA3074588A patent/CA3074588A1/en active Pending
- 2018-10-05 KR KR1020207012268A patent/KR102710877B1/ko active Active
-
2019
- 2019-03-29 US US16/370,726 patent/US20190218308A1/en not_active Abandoned
-
2020
- 2020-03-18 IL IL273414A patent/IL273414A/en unknown
-
2022
- 2022-07-28 US US17/876,164 patent/US20230099801A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020536109A5 (cg-RX-API-DMAC10.html) | ||
| JP7664357B2 (ja) | 抗ｍｅｔ抗体、ｍｅｔに結合する二重特異性抗原結合分子およびその使用方法 | |
| JP2020513809A5 (cg-RX-API-DMAC10.html) | ||
| JP7288920B2 (ja) | シンデカン－２のモジュレーターとその使用 | |
| TWI712423B (zh) | 抗ｔｒｏｐ２抗體-藥物結合物之製造方法 | |
| CN109563170B (zh) | 抗gitr抗体及其用途 | |
| AU2024202552A1 (en) | Neutralization of inhibitory pathways in lymphocytes | |
| NZ713461A (en) | Polypeptides and polynucleotides, and uses thereof for treatment of immune related disorders and cancer | |
| RU2017107559A (ru) | Лечение раковых заболеваний с применением анти-nkg2a средств | |
| RU2019111722A (ru) | Антитела против siglec-15 и способы их применения | |
| JP2017535257A5 (cg-RX-API-DMAC10.html) | ||
| RU2018119296A (ru) | Конъюгаты антитела, содержащие агонисты толл-подобного рецептора | |
| JP2009505676A5 (cg-RX-API-DMAC10.html) | ||
| JP2018521691A5 (cg-RX-API-DMAC10.html) | ||
| RU2011110405A (ru) | Агенты, связывающие рецептор frizzled и их применение | |
| RU2014101669A (ru) | Агенты, связывающие белки r-спондины (rspo), и способы их применения | |
| JP2018534933A5 (cg-RX-API-DMAC10.html) | ||
| RU2012137498A (ru) | Фармацевтическая композиция для лечения и/или профилактики рака | |
| RU2020115713A (ru) | Конъюгаты анти-cd71 активируемое антитело - лекарственное средство и способы их применения | |
| JP2015509962A5 (cg-RX-API-DMAC10.html) | ||
| JP2010535713A5 (cg-RX-API-DMAC10.html) | ||
| HRP20220918T1 (hr) | Anti-transtiretinska antitijela | |
| JP2013502913A5 (cg-RX-API-DMAC10.html) | ||
| RU2017127772A (ru) | Человеческие антитела к токсинам clostridium difficile | |
| JP2021502980A5 (cg-RX-API-DMAC10.html) |